Canagliflozin decreases serum uric acid level in diabetic patients with or without baseline hyperuricaemia
The present post hoc analysis of four placebo-controlled phase III trials revealed that canagliflozin is connected to an approximately 13 percent decrease in serum acid compared to placebo. Also, 23.5 and 32.4 percent of hyperuricaemic patients who received canagliflozin 100 and 300 mg, respectively, attained serum uric acid level of < 360 µmol/L (~ 6 mg/dL) compared to the 3.1 percent with placebo. The occurrence of kidney stones and gout were also low and similar throughout the groups.
Canagliflozin was concluded to lower serum uric acid in T2DM patients, including those who have hyperuricaemia initially.